A total of 23 patients received CPX-351 + MID and had sufficient data to be included in the analysis ...Preliminary results from the V-FAST trial suggest CPX-351 + MID is feasible, with a manageable safety profile and promising remission rates in adults with newly diagnosed AML who have a FLT3 mutation.